Podcast: Play in new window | Download (Duration: 7:35 — 6.9MB)
Subscribe: Apple Podcasts | Spotify | RSS
During the Asia-focused Episode 35 of Biotalk, Geoff Meyerson, CEO of Locust Walk, reviews key 2026 Q1 Report: Global Trends in Biopharma Transactions trends across China, Japan, and Korea.
China: Dominated global licensing with 66% of deal value -up from 48% in full-year 2025 -anchored by CSPC–AstraZeneca ($18.5B) and Innovent–Lilly ($8.5B). Venture financing surged to a three-year high of $1.2B across 17 deals, led by Corxel Pharmaceuticals’ $287M oral GLP-1 Series D. Out-licensing remains the dominant business model, now structural and increasingly central to global biopharma dealmaking.
Japan: Biotech stocks outperformed pharma (+10% vs. +8%), and the IPO market reopened after 18 months with Innovacell and J-Pharma raising $112M combined. Japan-based buyers licensed three programs averaging $1.2B in deal value, with 100% from early-stage programs -reflecting growing appetite for pipeline diversification.
Korea: The KOSPI rose 17%, though biotech stocks fell 14%. Venture financing rebounded to $125M across six deals, up from just $18M in Q4 2025, concentrated in early-stage oncology. Korean sellers drove the majority of licensing activity from non-major markets with two early-stage transactions averaging $405M.
Regional Takeaway: Q1 2026 confirmed Asia-Pacific’s rising centrality in global biopharma. China’s record out-licensing drove global deal value, Japan reopened its public markets, and Korea showed early signs of a cautious recovery.
Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.